FibroGen - FGEN Enterprise Value-to-Revenue Ratio

The EV/Sales ratio helps assess the fair value of FibroGen, Inc. (FGEN) amid rising sales of roxadustat and new oncology drugs. Revenues are based on government procurement and insurance payments for anemia treatment in China and the US. The company is currently optimizing expenses for survival and avoiding large-scale deals. The parameter value is -2787.95, which captures the real market valuation of the business accounting for debt.
fibrogen.com - analytical breakdowns and key metrics (FGEN)

For FibroGen, Inc., which outsources production and logistics to third-party contractors, this indicator allows for an assessment of capitalization efficiency excluding debt load. By analyzing the enterprise value-to-revenue multiple on the GURU.Markets platform, an investor can see the ratio of the total business value to sales volume, which helps filter out market noise and determine the fair value of FibroGen, Inc. within the context of its R&D strategy.